Shots:
- Insilico has entered into an exclusive out-licensing collaboration with TaiGen & its subsidiary TaiGen Biopharmaceuticals for ISM4808 to treat CKD-related anemia
- As per the deal, TaiGen will gain exclusive rights to ISM4808 & related forms for further development, commercialization & sub-licensing in Greater China, while Insilico will receive upfront payment, development & sales milestones, & tiered royalties, with the deal totaling double-digit millions
- ISM4808, a PHD inhibitor targeting the HIF-α pathway for CKD-related anemia, was empowered via Insilico’s Chemistry42, showed strong preclinical potency, oral PK & safety, plus received China IND clearance in 2023
Ref: PR Newswire| Image: Insilico & TaiGen | Press Release
Related News: Harbour BioMed Enters into a Collaboration with Insilico Medicine to Advance AI-Driven Antibody Discovery and Development
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
